The New York State Department of Health conditionally approved CombiMatrix Corp.'s (Nasdaq: CBMX) pre-implantation genetic screening by next generation sequencing sending the stock price up 35 cents to close at $3.05.
Conditional approval for CombiMatrix's screening
November 29, 2016 at 18:40 PM EST
